Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
2.430
+0.050 (2.10%)
At close: Feb 18, 2026, 4:00 PM EST
2.470
+0.040 (1.65%)
After-hours: Feb 18, 2026, 7:00 PM EST
Annovis Bio Employees
As of December 31, 2024, Annovis Bio had 15 total employees, including 8 full-time and 7 part-time employees. The number of employees decreased by 1 or -6.25% compared to the previous year.
Employees
15
Change (1Y)
-1
Growth (1Y)
-6.25%
Revenue / Employee
n/a
Profits / Employee
-$1,658,963
Market Cap
64.40M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 15 | -1 | -6.25% | 8 | 7 |
| Dec 31, 2023 | 16 | 11 | 220.00% | 6 | 10 |
| Dec 31, 2022 | 5 | 2 | 66.67% | 5 | 0 |
| Dec 31, 2021 | 3 | 1 | 50.00% | 3 | 0 |
| Dec 31, 2020 | 2 | 0 | - | 2 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pliant Therapeutics | 171 |
| MindWalk Holdings | 102 |
| Fractyl Health | 101 |
| ImmuCell | 84 |
| InflaRx | 74 |
| PMV Pharmaceuticals | 47 |
| Mereo BioPharma Group | 36 |
| NovaBay Pharmaceuticals | 14 |
ANVS News
- 6 days ago - Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's Disease - GlobeNewsWire
- 2 months ago - Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients - GlobeNewsWire
- 2 months ago - Annovis to Host Corporate Update Webinar on January 28, 2026 - GlobeNewsWire
- 2 months ago - Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group - GlobeNewsWire
- 3 months ago - Annovis Announces Two Presentations at the CTAD 2025 Conference - GlobeNewsWire
- 3 months ago - Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study - GlobeNewsWire
- 3 months ago - Annovis Bio Stock Jumps As New Data Shows Buntanetap Halts Cognitive Decline In Parkinson's Patients - Benzinga
- 3 months ago - Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients - GlobeNewsWire